GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Shiller PE Ratio

Pharmicell Co (XKRX:005690) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharmicell Co Shiller PE Ratio Historical Data

The historical data trend for Pharmicell Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co Shiller PE Ratio Chart

Pharmicell Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharmicell Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharmicell Co's Shiller PE Ratio

For the Biotechnology subindustry, Pharmicell Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmicell Co's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmicell Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Pharmicell Co's Shiller PE Ratio falls into.



Pharmicell Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Pharmicell Co's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Pharmicell Co's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-23/118.8477*118.8477
=-23.000

Current CPI (Mar. 2024) = 118.8477.

Pharmicell Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -71.000 99.353 -84.931
201409 -44.000 99.608 -52.499
201412 -454.000 99.098 -544.480
201503 -37.000 99.720 -44.097
201506 -20.000 100.050 -23.758
201509 -25.000 100.110 -29.679
201512 -34.000 100.220 -40.320
201603 -5.000 100.560 -5.909
201606 -13.000 100.790 -15.329
201609 12.000 101.460 14.056
201612 -6.000 101.560 -7.021
201703 -21.000 102.850 -24.266
201706 -27.000 102.610 -31.273
201709 -10.000 103.490 -11.484
201712 -318.000 102.990 -366.963
201803 -9.000 104.100 -10.275
201806 -7.000 104.130 -7.989
201809 -4.000 105.650 -4.500
201812 -194.000 104.350 -220.953
201903 17.000 104.490 19.336
201906 19.000 104.880 21.530
201909 -2.000 105.200 -2.259
201912 40.000 105.120 45.224
202003 14.000 105.540 15.765
202006 50.000 104.870 56.664
202009 12.000 106.200 13.429
202012 11.000 105.765 12.361
202103 32.000 107.357 35.425
202106 36.000 107.579 39.771
202109 60.000 108.759 65.566
202112 30.000 109.676 32.509
202203 53.000 111.806 56.338
202206 27.000 114.083 28.128
202209 41.908 114.831 43.374
202212 15.000 115.200 15.475
202303 12.000 116.550 12.237
202306 10.000 117.140 10.146
202309 17.840 119.111 17.801
202312 21.000 118.848 21.000
202403 -23.000 118.848 -23.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pharmicell Co  (XKRX:005690) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Pharmicell Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Pharmicell Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmicell Co (XKRX:005690) Business Description

Traded in Other Exchanges
N/A
Address
12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co (XKRX:005690) Headlines

No Headlines